21.10.2014 - Yet another European company is looking for money on the US stock exchange – French DBV Technologies SA is all set up for its secondary listing on NASDAQ. The French biotech company hopes to rake in US$98m for its peanut allergy patches.
The Bagneux-based food allergy specialist is currently listed on Euronext Paris, where it first went public in 2012. DBV intends to offer 4.3 million ADRs (American Depository Receipts) at US$23 per ADR – with two depository shares representing each ordinary share – to help finance its Phase IIb clinical trial of its product Viaskin Peanut (DBV-712) – an electrostatic patch for peanut allergy treatment.
The DBV was awarded Fast Track Designation from the FDA for its peanut allergy patch, which delivers biologically active compounds to the immune system through the skin. The French biotech company aims to begin Phase III trials in the first quarter of 2016. It also intends to initiate Phase I trials for its Viaskin Milk for cow’s milk protein allergy in children.
DBV’s primary shareholders at an undiluted basis are Sofinnova Partners (14%), Bpifrance (13%), Baker Brothers Investments (6%) and CEO Pierre-Henri Benhamou (4%). If the immunotherapy company is successful in its bid, it will have a fully diluted market value of US$964m.
The French biotech is not the only company looking for US financing: Recently, Forward Pharma raised a record US$220.5m with their IPO, while German Probiodrug AG and Swiss Molecular Partners AG are aiming for €32m and €145m, respectively.